A2 Biotherapeutics, Inc. | $80,000,000 | (Jan 10, 2025)
Holly | $2,200,000 | (Jan 10, 2025)
RLTYco | $20,000,000 | (Jan 10, 2025)
Certified by Founder
Lodge
RheumaGen
start up
United States
- Denver, Colorado
- 10/01/2025
- Series A
- $15,000,000
RheumaGen is a private biotechnology company engineering a new class of therapeutics to cure major autoimmune diseases at their source. RheumaGen focuses on editing the human leukocyte antigen (HLA), or “immune gene,” to develop one-time, curative cell and gene therapies. RheumaGen is headquartered in Aurora, Colorado. For more information, please visit rheumagen.com.
- Industry Biotechnology Research
- Website https://www.rheumagen.com/
- LinkedIn https://www.linkedin.com/company/rheumagen/
Air | $35,000,000 | (Jan 10, 2025)
Prudentia Sciences | $7,000,000 | (Jan 10, 2025)
Biosphere | $8,800,000 | (Jan 10, 2025)
RyboDyn Inc. | $4,000,000 | (Jan 10, 2025)
Light Horse Therapeutics | $62,000,000 | (Jan 10, 2025)
Abstract(US) | $4,800,000 | (Jan 10, 2025)
PrettyDamnQuick | $25,000,000 | (Jan 10, 2025)
Oxford Cancer Analytics | $11,000,000 | (Jan 10, 2025)